Upadacitinib – Medxy AI

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials

By MedXY 08/17/2026

Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.

Clinical Updates Dermatology news

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights

By MedXY 08/16/2026

This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging clinical and mechanistic data.

Dermatology Gastroenterology news

Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD

By MedXY 01/24/2026

An international multicenter study reveals that acne is a frequent adverse event in IBD patients treated with JAK inhibitors, particularly upadacitinib. The research highlights dose-dependency, significant psychosocial impacts, and the critical need for proactive dermatological management in clinical practice.

news Rheumatology

Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study

By MedXY 12/04/2025

In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with prior trials.

Gastroenterology news Specialties

Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis

By MedXY 08/14/2025

Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.

Clinical Updates news Rheumatology Specialties

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.